Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors
- PMID: 7589081
- DOI: 10.1002/eji.1830251020
Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors
Abstract
A recently described factor, interleukin-1 receptor antagonist binding factor (IL-1raBF), in serum of normal individuals is immunologically related to the interleukin-1 receptor type I (IL-1RI). It is presumably a soluble form of the receptor that binds exclusively to interleukin-1 receptor antagonist (IL-1ra). Recombinant soluble human IL-1RI expressed in COS cells (sIL-1RI) consists of the extracellular part of the receptor and binds all three known IL-1 species but preferentially to Il-1ra. We further characterized the sizes and binding of IL-1raBF and sIL-1RI to IL-1ra by polyacrylamide gel electrophoresis in the presence of sodium dodecylsulfate, ligand binding interference analyses, N-glycosidase treatment, concanavalin A affinity chromatography, and with the use of monoclonal antibodies (mAb) to human recombinant IL-1ra. We also evaluated the binding of IL-1ra to cellular IL-1RI on MRC5 fibroblasts and the interference afforded by the soluble receptors. The results show that the protein backbones of IL-1raBF and sIL-1RI are of similar size (approximately 35-40 kDa) and that there are differences in the glycosylation of the two molecules. These carbohydrates were necessary for optimal binding of both molecules to IL-1ra. Both factors blocked binding of IL-1ra to cellular IL-1RI, as did mAb to IL-1ra, but the sites on IL-1ra which bound to the mAb, and to IL-1raBF and sIL-1RI, differed. We conclude that there are important differences between the natural and recombinant forms of soluble IL-1RI and that IL-1ra binds differently to these molecules and to cellular IL-1RI.
Similar articles
-
Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids.J Immunol. 1994 Nov 15;153(10):4766-74. J Immunol. 1994. PMID: 7963543
-
Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II.J Immunol. 1997 Apr 15;158(8):3881-7. J Immunol. 1997. PMID: 9103457
-
Mapping of receptor binding sites on IL-1 beta by reconstruction of IL-1ra-like domains.J Immunol. 1995 Nov 15;155(10):4719-25. J Immunol. 1995. PMID: 7594472
-
The interleukin-1 receptor antagonist and its delivery by gene transfer.Receptor. 1994 Spring;4(1):9-15. Receptor. 1994. PMID: 8038709 Review.
-
Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis.Autoimmunity. 2010 Jun;43(4):255-63. doi: 10.3109/08916930903305641. Autoimmunity. 2010. PMID: 19845478 Review.
Cited by
-
Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.World J Orthop. 2014 Sep 18;5(4):516-36. doi: 10.5312/wjo.v5.i4.516. eCollection 2014 Sep 18. World J Orthop. 2014. PMID: 25232528 Free PMC article. Review.
-
Administration of intravenous immunoglobulin (IVIG) in vivo--down-regulatory effects on the IL-1 system.Clin Exp Immunol. 1999 Jan;115(1):136-43. doi: 10.1046/j.1365-2249.1999.00757.x. Clin Exp Immunol. 1999. PMID: 9933433 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources